Agios drug approved in USA for certain acute myeloid leukemia patients

East Coast, USA-based Agios Pharmaceuticals (Nasdaq: AGIO) has won approval in the USA for Tibsovo (i Tibsovo), a treatment for certain patients with relapsed or refractory acute myeloid leukemia.

Agios, which studies the role of cellular metabolism to treat cancer and rare genetic diseases, announced that Tibsovo is now the first and only FDA-approved therapy for this particular patient population.

Chief executive David Schenkein said: “The FDA approval of Tibsovo, our first wholly-owned drug and the second approved medicine from our research platform in less than a year – is an incredibly exciting milestone for our company.”